文献速递前列腺癌

未治疗前列腺癌自然病史:长期进展模式与生存结局综述

Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2026-03-06

该综述系统检索了1990-2025年PubMed、EMBASE和Cochrane数据库,纳入15项报告未治疗或保守管理前列腺癌患者≥10年结局的研究,共43,127例患者,中位随访15-30年。结果显示肿瘤分级是最强预后因素,低级别病变常惰性15-20年,而高级别肿瘤数年内进展为致死性疾病,支持低危患者主动监测、高危患者早期干预。

要点

  • 肿瘤分级是未治疗前列腺癌自然病史中最强预后因素。
  • Gleason 6肿瘤10年前列腺癌特异性生存>95%,Gleason 8-10则<60%。
  • Grade Group 1肿瘤15-20年转移风险<5%,Grade Groups 4-5中位疾病特异性生存<5年。

核心结论

  • 肿瘤分级是未治疗前列腺癌自然病史中最强预后因素,低级别病变常惰性15-20年,高级别肿瘤常数年内进展为致死性疾病。

研究设计与样本

  • 系统综述检索PubMed、EMBASE和Cochrane数据库(1990-2025年),纳入15项报告未治疗或保守管理前列腺癌患者≥10年结局的观察性队列、人群登记和荟萃分析,共43,127例患者,中位随访15-30年。

主要发现

  • 10年前列腺癌特异性生存从Gleason 6肿瘤的>95%到Gleason 8-10疾病的<60%不等。
  • Grade Group 1肿瘤15-20年转移风险<5%,而Grade Groups 4-5中位疾病特异性生存<5年。
  • 所有风险组中,疾病进展在15年后显著加速。
  • 75岁后确诊男性面临约57-60%的10年非癌死亡率,与肿瘤分级无关。

临床怎么用

  • 研究结果支持对低危患者采用当代主动监测方案,并为高危疾病的循证治疗决策提供依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: We systematically reviewed the long-term outcomes of untreated prostate cancer across different risk categories to inform treatment decisions and active surveillance protocols. This comprehensive analysis synthesizes long-term progression data across tumor staging and grading systems. MATERIALS AND METHODS: We conducted a systematic literature search of PubMed, EMBASE, and Cochrane databases (1990-2025) for studies reporting ≥10-year outcomes in untreated or conservatively managed prostate cancer patients. Eligible studies included observational cohorts, population registries, and meta-analyses. Primary endpoints included prostate cancer-specific mortality, metastatic progression, and competing mortality. RESULTS: Fifteen major studies encompassing 43,127 patients (median follow-up 15-30 years) demonstrated heterogeneous progression patterns. Ten-year prostate cancer-specific survival ranged from >95% for Gleason 6 tumors to <60% for Gleason 8-10 disease. Grade Group 1 tumors showed <5% metastatic risk over 15-20 years, while Grade Groups 4-5 exhibited rapid progression with median disease-specific survival <5 years. Across all risk groups, disease progression accelerated markedly after 15 years. Men diagnosed after age 75 faced substantial competing mortality (~57-60% 10-year non-cancer mortality), regardless of tumor grade. CONCLUSIONS: Tumor grade is the strongest prognostic factor in the natural history of untreated prostate cancer. Low-grade disease often remains indolent for 15-20 years, whereas high-grade tumors frequently progress to lethal disease within a few years, warranting early intervention. These findings support contemporary active surveillance protocols for low-risk patients and inform evidence-based treatment decisions for higher-risk disease. Summary with methodological context.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Tewari AK, Mehrazin R, Wiklund P, et al. Natural history of untreated prostate cancer: a comprehensive review of long-term progression patterns and survival outcomes. Prostate Cancer Prostatic Dis. 2026. PMID: 41792475. doi:10.1038/s41391-026-01095-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。